Highlights Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Market Closed - Nasdaq Other stock markets 01:30:00 15/05/2024 am IST			5-day change	1st Jan Change
1.91 ^USD	-1.55%		-6.83%	+35.46%

24/04	Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	CI
17/04	Clarify Pharma to change name to File Forge Technology	AN

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	24/04	CI
Clarify Pharma to change name to File Forge Technology	17/04	AN
Atai Life Sciences Announces the Publication of Beckley Psytech?s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology	17/04	CI
Sector Update: Health Care Stocks Softer Late Afternoon	04/04	MT
Atai Life Sciences N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Atai Life Sciences N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03	CI
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech?s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression	27/03	CI
Atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01	04/03	CI
Atai Life Sciences Acquires Stake in Beckley Psytech	05/01	MT
Atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)	02/01	CI
IntelGenx Announcing Shareholder Approval of Financing Transactions	29/11	MT
Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Atai Life Sciences N.V. acquired remaining stake of DemeRx IB, Inc. for $16 million.	14/11	CI
Atai Life Sciences N.V. Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants	03/23/03	CI
IntelGenx Closes First Tranche of Private Placement From Strategic Partner For Aggregate Proceeds of US$3 Million	31/23/31	MT
Atai Life Sciences N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine)	09/23/09	CI
Atai Life Sciences N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting	28/23/28	CI
Atai Life Sciences N : Company Presentation April 2023	13/23/13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Highlights

Filters